The significance of serum active matrix metalloproteinase-9 in patients with non-small cell lung cancer

Lung Cancer

Volumn 46, Issue 2, 2004, Pages 205-213

  Ondo, Kaoru ^a,b   Sugio, Kenji ^a,c   Yamazaki, Koji ^a   Yamaguchi, Masafumi ^a   Yano, Tokujiro ^a   Yoshino, Ichiro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b MATSUYAMA RED CROSS HOSPITAL   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Active matrix metalloproteinase 9; Lung cancer; Matrix metalloproteinase 9; Metastasis; Tumor marker

Indexed keywords

GELATINASE B;

ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 4944234684     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.030     Document Type: Article

References (38)

1. Liotta L.A., Stetler-Stevenson W.G., Steeg P.S. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest. 9:1991;543-551
2. Roos E., Dingemans K.P. Mechanisms of metastasis. Biochim. Biophys. Acta. 560:1979;135-166
3. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 6:1990;121-125
4. Huhtala P., Tuuttila A., Chow L.T., et al. Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem. 266:1991;16485-16490
5. Birkedal-Hansen H., Moore W.G., Bodden M.K., et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol M. 4:1993;197-250
6. Okada Y., Gonoji Y., Naka K., et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem. 267:1992;21712-21719
7. Heussen C., Dowdle E.B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem. 102:1980;196-202
8. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 218:1994;325-329
9. Leber T.M., Balkwill F.R. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem. 249:1997;24-28
10. Hanemaaijer R., Visser H., Konttinen Y.T., et al. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol. 17:1998;657-665
11. Zucker S., Lysik R.M., Zarrabi M.H., et al. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 53:1993;140-146
12. Torii A., Kodera Y., Uesaka K., et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg. 84:1997;133-136
13. Endo K., Maehara Y., Baba H., et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res. 17:1997;2253-2258
14. Iizasa T., Fujisawa T., Suzuki M., et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res. 5:1999;149-153
15. Nielsen B.S., Timshel S., Kjeldsen L., et al. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer. 65:1996;57-62
16. Pyke C., Ralfkiaer E., Tryggvason K., et al. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol. 142:1993;359-365
17. Wilhelm S.M., Collier I.E., Marmer B.L., et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 264:1989;17213-17221
18. Tryggvason K., Hoyhtya M., Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res TR. 24:1993;209-218
19. Kleiner D.E. Jr., Stetler-Stevenson W.G. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol. 5:1993;891-897
20. Schutz A., Schneidenbach D., Aust G. Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol. 23:2002;179-184
21. Laack E., Kohler A., Kugler C., et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol. 13:2002;1550-1557
22. Jeffers M., Rong S., Vande W.G.F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell. Biol. 16:1996;1115-1125
23. Weimar I.S., de J.D., Muller E.J., et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood. 89:1997;990-1000
24. Teti A., De G.A., Spinella M.T., et al. Transforming growth factor-beta enhances adhesion of melanoma cells to the endothelium in vitro. Int J Cancer. 72:1997;1013-1020
25. Zhang M., Wang M.H., Singh R.K., et al. Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts. J Biol Chem. 272:1997;14139-14146
26. Pei X H., Nakanishi Y., Takayama K., et al. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer. 79:1999;40-46
27. Woessner J.F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154
28. Murphy G., Docherty A.J. The matrix metalloproteinases and their inhibitors. Am J Resp Cell Mol. 7:1992;120-125
29. Docherty A.J., Murphy G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis. 49:1990;469-479
30. Nuovo G.J., MacConnell P.B., Simsir A., et al. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 55:1995;267-275
31. Arnold SM, Toung AB, Munn RK, et al. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in paired primary tumors and brain metastasis, Clin Cancer Res 1999;5:4028-33.
32. Gonzalez-Avila G., Iturria C., Vadillo F., et al. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology. 66:1998;5-16
33. Thomas P., Khokha R., Shepherd F.A., et al. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol. 190:2000;150-156
34. Chirivi R.G., Garofalo A., Crimmin M.J., et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 58:1994;460-464
35. Taraboletti G., Garofalo A., Belotti D., et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst. 87(4):1995;293-298
36. Nemunaitis J., Poole C., Primrose J., et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 4:1998;1101-1109
37. Yamamoto A., Yano S., Shiraga M., et al. A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int J Cancer. 103:2003;822-828
38. Liu J., Tsao M.S., Pagura M., et al. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung Cancer. 42:2003;335-344